CoImmune Inc. inks all-stock merger deal with Formula Pharmaceutical
Category: #health  By Mateen Dalal  Date: 2020-01-16
  • share
  • Twitter
  • Facebook
  • LinkedIn

CoImmune Inc. inks all-stock merger deal with Formula Pharmaceutical
  • The merger will bring two therapeutic immune-oncology platforms together
  • Focus shall be placed over Phase 1 and Phase 2 trials of CAR-CIK and CMN-001 respectively

U.S.-based bioscience firm CoImmune, Inc., announces partnership with Formula Pharmaceuticals, Inc., a privately-held biopharma firm based in the U.S., as it brings two of the prime therapeutic immune-oncology platforms together. The collaboration of Formula Pharmaceuticals with CoImmune will further provide access to all the tangible and intangible assets of Formula Pharmaceuticals.

Following the completion of the merger, the partnered company shall focus on the running of lead asset CMN-001’s Phase 2b trial in enhanced renal cell carcinoma as well as a Phase 1 study of CAR-CIK (killer cells induced by cytokine)’s for acute lymphoblastic leukemia.

CAR-CIK, an allogenic, propriety non-viral technology platform bears the potential to surpass the commercial limitations associated with the existing CAR-T that needs autologous viral and blood transfection. The closure of the deal shall be accompanied by an investment of $6 million in the combined entity that could further fund the CAR-CIK program.

CoImmune’s Chief Executive Officer, Charles Nicolette stated that the company is looking forward to bringing two therapeutic immune-oncology platforms together in order to maximize its commercial and clinical value resulting from the merger. 

He further added that CoImmune runs a powerful Phase 2b program with CMN-001, the lead candidate along with a strong team to help advance its pipeline. The company has accessed several potential acquisition and merger opportunities and also believes that Formula owns the best allo CAR-based technology as well as a strong investor base that is capable of delivering a considerable value.

Both the companies complement each other and the combination of both shall help CoImmune to advance its therapies for FDA approval.

Sources confirm that CoImmune has been planning to carry out sponsored research contracts with the University of Milano-Bicocca, MBBM Foundation, San Gerardo Hospital and M. Tettamanti Research Center to be able to conduct all the non-clinical research and various other important work to develop CAR-CIK  in Monza, Italy.

 

Source Credit- https://markets.businessinsider.com/news/stocks/coimmune-inc-a-us-based-clinical-stage-biotech-and-formula-pharmaceutical-inc-agree-to-merge-in-an-all-stock-transaction-1028821317

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Microsoft to fix an active security flaw in Internet Explorer
Microsoft to fix an active security flaw in Internet Explorer
By Mateen Dalal

Microsoft, the renowned American tech giant, reportedly verified the presence of a security flaw that is affecting Internet Explorer (IE) and is being used by hackers. The company also said it is working to find a fix for this bug, which would be rel...

Dermtech signs a commercial & medicare advantage coverage agreement
Dermtech signs a commercial & medicare advantage coverage agreement
By Mateen Dalal

DermTech Inc., a San Diego based biotechnology company that is involved in precision dermatology, has recently announced signing a contract with a regional health plan to develop its gene expression based PLA (Pigmented Lesion Assay) for prior detect...

Adverum reviews recent business progress and unveils its 2020 outlook
Adverum reviews recent business progress and unveils its 2020 outlook
By Mateen Dalal

Adverum Biotechnologies, a California based biotech company, has reportedly announced that it has examined its recent business & development progress. The company has also unveiled its outlook for 2020. Leone Patterson, president and chief execu...